Merck's COVID-19 pill isn't quite as effective as initially reported

Pharmaceutical companies Merck and Ridgeback Biotherapeutics have published an update on molnupiravir, a pill formulated to help treat COVID-19 by reducing one’s risk of being hospitalized with or dying from the disease. According to the latest details from the company, molnupiravir isn’t quite as effective as the interim analysis had previously found. Merck and Ridgeback published the update on the …